Adam Paduszynski
Family Medicine · Bayonne, NJNPI 1609869650
Payments from drug & device makers
Across 75 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$402
- Amgen$247
- Merck$245
- AVEO Pharmaceuticals, Inc.$67
- E.r. Squibb & Sons, L.L.C.$57
- Novartis$56
- plus $481 from 18 others
What the payments were for
- Food & beverage$1,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 17 | $402 |
| Amgen | 9 | $247 |
| Merck | 12 | $245 |
| AVEO Pharmaceuticals, Inc. | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Novartis | 3 | $56 |
| Bayer | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Lilly USA, LLC | 3 | $46 |
| Novocure Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34 |
| Pfizer | 2 | $32 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Octapharma USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,556 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $36,984 |
| EliquisApixaban | 42 | $32,846 |
| VemlidyTenofovir Alafenamide | 13 | $18,844 |
| Omeprazole | 30 | $297 |
| Pantoprazole Sodium | 16 | $284 |
| Atorvastatin Calcium | 29 | $185 |
| Olanzapine | 11 | $181 |
| Montelukast Sodium | 18 | $168 |
| Tamoxifen Citrate | 14 | $160 |
| Zolpidem Tartrate | 16 | $154 |
| Nortriptyline Hcl | 18 | $116 |
| Levothyroxine Sodium | 29 | $107 |
| ClopidogrelClopidogrel Bisulfate | 11 | $106 |
| Diltiazem Hcl | 15 | $99 |
| Ondansetron OdtOndansetron | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $32,84642 claims |
| Lilly USA, LLCOlanzapine | $46 | $18111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Bayonne
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.